RE: Slow5 Feb 2026 08:58
Thanks PCS .. AI gave me
Overall Progress & Outlook
Dr Parker concluded the AGM update with the following points: 
• 2025 saw substantial pipeline progress, including positive Phase 1 SDC-1801 data and process improvements. 
• Despite delays in toxicology work, the study is now back on track. 
• Improved economics on SRA737 and partnering discussions across key programmes enhance value creation. 
• A new TYK2 neuroscience collaboration adds further potential for future growth. 
• Sareum enters the next period with strengthened IP, a clear operational roadmap, and sufficient financial resources underpinned by shareholder support. 
Patience may still be rewarded.